All Videos Tagged biotechnology (MedTech I.Q.) - MedTech I.Q.

Venture:Part 1 - Mark Heesen Presentation at BioWest 2010

2010-10-17T18:09:53.129Z

COBioscience | October 09, 2010

Recorded Sept 30, 2010, at the Denver Grand Hyatt. Presenter: Mark G. Heesen, President, National Venture Capital Association.Mark Heesen has advocated for the venture capital industry, entrepreneurship and innovation for nearly two decades, first as NVCA's head of public policy and since 1999 as the Association's president. Under Mark's leadership, the NVCA has grown in both scope and scale as it relates to its public policy agenda, research initiatives, and member programs. Mark is constantly engaged in legislative and regulatory issues surrounding information technology, life sciences and clean technology investing, providing strategic direction for the NVCA professional staff and managing a board of twenty-six venture capital practitioners.

Informatics: Obstacles to Unlocking the Human Genome

2009-06-29T14:22:58.320Z

A panel of DNA, policy, and research experts analyze the social implications of pharmaceutical companies and universities patenting the human genome. Ballon compares the argument against releasing genetic information to a 1961 study of cancer diagnosis.

-----

Personal genomic testing (the analysis of the DNA of individuals) is now available for less than $400. The consequences of personal genetic testing are often debated, with advocates arguing that genetic data can lead to improved health care and critics warning that consumers may be unduly worried upon learning results.

California regulations impose conditions on firms providing personal genomic testing. This symposium examines genomic testing technology, its ramifications, government regulation of the industry, and whether individuals should have their genome analyzed. - Commonwealth Club of California

Linda Avey has over 20 years of sales and business development experience in the biopharmaceutical industry in San Francisco, Boston, San Diego, and Washington, D.C. Prior to starting 23andMe, she developed translational research collaborations with academic and pharmaceutical partners for Affymetrix and Perlegen Sciences. Avey also spent time at Spotfire helping scientists understand the power of data visualization and at Applied Biosystems during the early days of the human genome project. The advent of high density genome-wide scanning technologies brought huge potential for significant discoveries. However, the lack of sufficient funding to enable adequate studies prompted Avey to think of a new research model. These ideas led to the formation of 23andMe. Her primary interest is the acceleration of personalized medicine, using genetic profiles to target the right drug to the right person at the correct dose. Avey graduated from Augustana College with a B.A. in biology.

Daniel Ballon is Senior Policy Fellow in Technology Studies at the Pacific Research Institute. Dr. Ballon's research focuses on policies which promote innovation in the technology sector. He previously spent ten years conducting applied research in biotechnology, and his work has been published in leading biomedical journals. Prior to joining PRI, he served as science and technology policy advisor for former Speaker of the House Newt Gingrich at the American Enterprise Institute. Dr. Ballon received his Ph.D. in Molecular and Cell Biology from the University of California at Berkeley and a B.A. in Molecular Biology and Biochemistry from Wesleyan University.

David C. Magnus, Ph.D. is Associate Professor of Pediatrics and Medicine, Stanford University. Magnus is also Director of the Stanford Center for Biomedical Ethics.

Strategy: Case Study, Life Science Cluster - Medicon Valley (Denmark/Sweden)

2008-10-31T03:25:01.568Z

Medicon Valley (www.mva.org) is a binational cluster that spans the island of Zeeland in eastern Denmark and the Skåne region of southern Sweden. Medicon Valley is one of Europe's strongest life science clusters.

More than 300 life science companies are presently located in Medicon Valley.

Medicon Valley Alliance is the cluster organisation for the Danish-Swedish life science cluster Medicon Valley.

As a non-profit, fee based member organisation, they serve as project leader on cross border initiatives, adding to Medicon Valley's position as a world class life science cluster. They create synergies and value for our 250 members, who include universities, hospitals and human life science companies.

Medicon Valley lies in the Øresund Region, which includes the regions of Greater Copenhagen and Zealand in Denmark and Skåne in Sweden.

Strategy: Florida Innovators in Life Science

2008-10-31T03:20:42.403Z

The life sciences in Florida continue to thrive thanks to a number of innovators in biotechnology, medical devices, pharmaceuticals and healthcare. Learn about some of these talented professionals and their contributions to life sciences innovation in the following stories. http://www.eflorida.com/innovationcenter

Systems Biology: Craig Venter - On the verge of creating synthetic life

2008-09-27T17:04:38.706Z

"Can we create new life out of our digital universe?" asks Craig Venter, who was instrumental in decoding the human genome sequence. And his answer is, yes, and pretty soon. He walks the TED2008 audience through his latest research into "fourth-generation fuels" -- biologically created fuels with CO2 as their feedstock. His talk covers the details of creating brand-new chromosomes using digital technology, the reasons why we would want to do this, and the bioethics of synthetic life. A fascinating Q&A with TED's Chris Anderson follows (two words: suicide genes).
TedTalks, http://www.ted.com